Health ❯ Chronic Conditions ❯ Obesity

Treatment Options

Injectable Medications Small-Molecule Drugs Patient Testimonials Patient Experiences Lifestyle Changes Oral Medications Zepbound Medication Efficacy GLP-1 Receptor Agonists Patient Outcomes GLP-1 Medications GLP-1 Therapy GLP-1 Drugs Patient Preferences Ozempic Wegovy Novo Nordisk Patient Demographics Medication Management Weight Loss Medications

Lilly’s GLP‑1 Sales and PBM Coverage Fuel Record Quarter as Pipeline Logs Durable Wins

Expanded payer coverage will raise patient access by lowering out‑of‑pocket costs for Lilly’s obesity medicines.

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

Lilly's Rally Deepens as U.S. Access Deal Recasts Outlook for GLP‑1 Drugs

White House Clinches GLP-1 Price Deal as Lilly Sets Zepbound and Pill Pricing